Please assess the completion status of the following clinical trial:

Trial Title: A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects with a diagnosis of first AIS due to distal \[M2 segment and beyond\] occlusion or perforator occlusion~* Perfusion abnormalities observed on Computed Tomography Perfusion (CTP)~* Mild to moderate stroke severity~* Pre-stroke mRS \<4~* Written informed consent obtained from patient and/or medical treatment decision maker prior to study-start (upon admission).~Exclusion Criteria:~* Administration of intravenous thrombolytic therapy in distal occlusion as etiology of AIS~* Intervention by endovascular thrombectomy (EVT)~* Known allergy or anaphylaxis to adrenocorticotropic hormone (ACTH) or melanocortins or any of the excipients listed in the Investigator's Brochure~* Any evidence of hepatic (defined as three times standard range) or renal impairment (defined as estimated glomerular filtration rate (eGFR) \<50 mL/min/1.73 m²)~* Any other medical condition which may interfere with the study protocol~* Female who is pregnant (confirmed by positive serum beta human chorionic gonadotropin (β-HCG) pregnancy test prior to baseline) or lactating~* Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device) or a lifestyle excluding pregnancy~* Unable to undergo MRI brain evaluation~* Not suitable for trial participation according to judgment of the Principal Investigator (PI)~* Patients starting afamelanotide 24 hours or more from ictus.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Afamelanotide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).